Home » Oncothyreon Initiates Phase III Trial of Stimuvax in Asian Patients With NSCLC
Oncothyreon Initiates Phase III Trial of Stimuvax in Asian Patients With NSCLC
Oncothyreon Inc. Thursday announced that Merck KGaA of
Darmstadt, Germany, has initiated a Phase 3 trial of Stimuvax (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC).
SunHerald
SunHerald
Upcoming Events
-
07May
-
14May
-
30May